GPGI INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against GPGI, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit

GPGI is hit with a securities class action tied to its Nov. 3, 2025 Husky Technologies acquisition, alleging materially overstated Husky value and lack of reasonable basis for targets. After 4Q25/FY25 results showed Husky pro forma Adjusted EBITDA down (4Q25: $136.1M, -5.4% YoY; margins -318 bps to 26.1%), GPGI stock fell 16% over two days. The May 7, 2026 1Q26 update and guidance cut further pressured shares, with pro forma net sales at $290.8M (-5.2% YoY) and pro forma Adjusted EBITDA at $38.0M (-40.2% YoY), and guidance lowered for 2026 net sales to $1.95B–$2.10B and Adjusted EBITDA to $550M–$610M; the stock fell nearly 26% on the news.

Analysis

This is less about the lawsuit and more about the market finally pricing in that the acquisition thesis may have been built on aggressive adjusted numbers. Once investors stop believing management can reliably translate reported sales into cash earnings, the equity rerates like a higher-risk roll-up: lower multiple, higher equity risk premium, and a wider gap between headline growth and economic profit. That usually persists for 6-18 months until there is either a clean forensic disclosure or a new strategic owner.

The second-order damage is broader than one name. Capital allocators will discount any sponsor-backed industrial deal with a large non-core add-on, which can pressure similar acquisition-heavy small/mid-cap names and reduce appetite for complex financed M&A. If Husky’s margin profile is truly deteriorating, the relevant loser is not just CMPO/GPGI equity holders; it is also the lender base and any supplier ecosystem that depended on capex normalization and smoother working-capital conversion.

Near term, the stock can still bounce on technicals because litigation announcements do not change cash flow today, but the overhang keeps every guidance update under a microscope. The key falsifier is simple: sustained segment-level EBITDA stabilization plus no further downward revisions over the next two quarters. Absent that, the market will treat each filing as incremental evidence of governance weakness rather than a one-off legal event.

Contrarian view: consensus may be underestimating how much of the downside is already in the tape, but also underestimating how sticky the discount becomes once a company loses credibility on an acquired segment. If disclosure quality improves quickly, the stock could mean-revert; if not, this is a classic case where the first cut is not the deepest, because the real hit comes from covenant/funding flexibility and a permanently lower multiple.

Key Decisions for Investors

• Short GPGI/CMPO on any 1-2 day relief rally over the next 2-4 weeks; this is a multiple-overhang trade, not a fundamentals re-entry, with upside likely capped until there are two clean quarters of segment stability.
• Use 1-3 month put spreads on GPGI only if options are liquid; prefer spreads over outright puts because the immediate tape reaction may be partly exhausted, but another disclosure miss could re-open the gap lower.
• Pair long cleaner industrial equipment names such as DOV or NDSN against short GPGI/CMPO for 1-3 months; the relative trade benefits from governance premium migration toward higher-quality, simpler cash-flow stories.
• Do not add to RHLD exposure until there is clarity on any legal settlement or sponsor-related fee recovery; reputational damage can impair future deal economics even if direct financial liability is limited.
• Set a watch item on the next quarterly filing: any further Husky EBITDA miss or guide cut is the trigger to increase the short; a stable sequential EBITDA bridge is the main thesis falsifier.